COLLEGE ENGLISH最新文献

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity. 直接口服抗凝剂治疗肥胖症静脉血栓栓塞。

IF 1.1 3区文学

COLLEGE ENGLISH Pub Date : 2023-12-01 Epub Date: 2023-09-04 DOI: 10.1177/87551225231196748

Quinn Hattaway, Jessica A Starr, Nathan A Pinner

{"title":"Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity.","authors":"Quinn Hattaway, Jessica A Starr, Nathan A Pinner","doi":"10.1177/87551225231196748","DOIUrl":"10.1177/87551225231196748","url":null,"abstract":"Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a decreased risk of bleeding when compared to warfarin for the treatment of venous thromboembolism (VTE). In patients with obesity, there are limited data regarding the safety and efficacy of DOACs. Despite concerns for both under- and over-dosing patients with extremes of body weight, there are no dose adjustment recommendations in the package inserts for any of the DOACs. Objective: To evaluate the safety and efficacy of DOACs versus warfarin for the treatment of VTE in patients with obesity. Methods: This single-center, retrospective cohort study included obese patients initiated on DOAC or warfarin therapy for VTE from January 2015 to January 2022. Patients with cancer, hypercoagulable disorders, end-stage kidney disease, or pregnancy were excluded. The primary endpoint was VTE recurrence. Secondary endpoints included major and minor bleeding. Results: A total of 120 patients met criteria for inclusion. Ninety-two received DOAC therapy and 28 received warfarin. The primary endpoint occurred in 4 patients in the DOAC group and 3 patients in the warfarin group (P = 0.35). Major bleeding occurred in 2 patients. Minor bleeding events occurred in 10 (8.33%) patients. Of those, 6 (6.5%) events occurred in patients receiving a DOAC and 4 (14.3%) events occurred in patients receiving warfarin (P = 0.28). Limitations of this study include the retrospective single-center study design. Conclusions: There was a comparable risk of bleeding and recurrent VTE between DOACs and warfarin in patients initiated on therapy for VTE.","PeriodicalId":51657,"journal":{"name":"COLLEGE ENGLISH","volume":"19 1","pages":"269-273"},"PeriodicalIF":1.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90400658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"文学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}